Summary
Pfizer Inc. (PFE) has filed an 8-K report on February 4, 2025, announcing its financial results for the fourth quarter and the full year of 2024. The report primarily serves to furnish a press release detailing these financial outcomes, which was issued on the same day. Investors should refer to the furnished press release (Exhibit 99) for specific details regarding revenue, earnings, and any forward-looking guidance provided by the company. While this 8-K does not contain new operational or financial disclosures beyond the press release, it signifies the official release of Pfizer's latest performance data. The company is providing this information to ensure timely and broad dissemination of its financial condition and results of operations to the public and the investment community.
Key Highlights
- 1Pfizer Inc. (PFE) filed an 8-K on February 4, 2025.
- 2The filing announces Pfizer's financial results for Q4 and full-year 2024.
- 3A press release detailing these results was issued on February 4, 2025 (Exhibit 99).
- 4Investors should consult the provided press release for specific financial performance data.
- 5The information furnished is for informational purposes and not deemed 'filed' under Section 18 of the Exchange Act unless specifically incorporated by reference.
- 6The filing includes an Exhibit Index listing the press release and an interactive data file.